Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesSummit Therapeutics PLC

Summit Therapeutics PLC

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
16.75 USD -1.08 ( 6.06%)
Last update at 2026-11-11T20:54:00Z
VOLUME
3201831
Market Cap
1832.17M
P/E
6.87

Momentum Score

…

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
16.59
Low
17.92
High
52 Week Price Range
1.52
Low
5.39
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Summit Therapeutics is a clinical-stage biopharmaceutical company developing targeted antibiotics and microbiome-preserving therapies, with a lead program for Clostridioides difficile infection. Long-term growth drivers are clinical progress toward approval, potential partnerships or commercialization, and demand for microbiome-sparing infection treatments.

Primary risks are clinical and regulatory failure, need for additional financing, and intense competition in the antibiotic and microbiome therapy markets.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
17.83
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.70M
Debt / Equity
1.37
ROE
-130.59%
Net Debt
34.67M
ROCE
-39.49%
Diluted EPS TTM
0.38

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Type yearly yearly yearly yearly yearly
Date 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Income before tax -78.78M -88.60M -52.91M 4.99M 6.60M
Minority interest - - - - 0.00M
Net income -74.38M -86.15M -52.70M 4.99M 9.87M
Selling general administrative 26.70M 23.61M 19.23M - 16.19M
Gross profit 0.70M 1.81M 0.86M 43.01M 56.39M
Reconciled depreciation 2.51M 2.46M 2.00M - 1.49M
Ebit -72.09M -88.64M -53.19M -25.56M 12.38M
Ebitda -60.80M -86.19M -51.48M 15.16M 13.87M
Depreciation and amortization 11.29M 2.46M 1.72M 0.52M 1.49M
Non operating income net other - - - - 0.00M
Operating income -72.09M -86.19M -53.19M 15.16M 12.38M
Other operating expenses 64.28M 88.00M 53.19M -39.18M 47.69M
Interest expense 4.40M 0.28M 0.26M 0.00M 0.56M
Tax provision - 0.00M -0.21M - -3.27M
Interest income - 0.00M 0.00M - 0.01M
Net interest income -4.40M -0.28M -0.25M - 3.10M
Extraordinary items - - - - 0.00M
Non recurring - - - - 0.00M
Other items - - - - 0.00M
Income tax expense -4.40M -2.46M -0.21M -3.84M -3.27M
Total revenue 0.70M 1.81M 0.86M 43.01M 56.41M
Total operating expenses 64.28M 88.00M 53.19M -39.18M 47.69M
Cost of revenue - - - - 0.02M
Total other income expense net -6.69M -2.42M 0.28M -10.16M -5.78M
Discontinued operations - - - - 0.00M
Net income from continuing ops -78.78M -88.60M -52.70M - 9.87M
Net income applicable to common shares -78.78M -88.60M -52.70M -24.03M 7.53M
Preferred stock and other adjustments - - - - 0.00M
Breakdown 2024-01-31 2023-01-31 2022-01-31 2021-01-31 2020-01-31
Type yearly yearly yearly yearly yearly
Date 2024-01-31 2023-01-31 2022-01-31 2021-01-31 2020-01-31
Total assets 202.95M 664.17M 113.37M 102.50M 24.44M
Intangible assets - - 10.40M 11.52M 10.60M
Other current assets 0.18M 0.49M 1.20M 1.52M 5.80M
Total liab 125.26M 537.51M 30.09M 23.05M -18.10M
Total stockholder equity 77.69M 126.65M 83.28M 79.45M 42.54M
Other current liab 0.72M 16.97M 12.22M 4.99M 1.49M
Common stock 7.02M 2.11M 0.98M 0.83M 3.36M
Capital stock 7.02M 2.11M 0.98M 0.83M -
Retained earnings -993.26M -378.33M -299.55M -214.74M -97.62M
Other liab - 1.43M 2.78M 3.08M 3.98M
Good will 1.89M 1.80M 2.01M 2.03M 1.81M
Other assets - 0.58M 25.52M - -16.38M
Cash 71.42M 348.61M 71.79M 66.42M 26.86M
Total current liabilities 20.41M 38.78M 25.62M 19.89M -1.84M
Current deferred revenue 14.21M - 7.94M 8.37M -0.83M
Net debt 34.67M 170.16M -69.01M -65.95M -27.86M
Short term debt 2.81M 21.46M 1.09M 0.39M -1.00M
Short long term debt - 19.77M - - -
Short long term debt total 106.10M 518.76M 2.78M 0.47M -1.00M
Other stockholder equity 1066.38M 504.77M 384.05M 293.37M 42.54M
Property plant equipment - 5.08M 3.48M 1.28M 1.17M
Total current assets 189.71M 656.71M 97.31M 66.42M 26.86M
Net tangible assets - 124.86M 70.88M 23.43M 47.46M
Short term investments 114.82M - - - -
Net receivables 0.85M 6.12M 17.16M 10.19M 5.13M
Long term debt 100.00M 494.54M - - -
Inventory 2.44M 301.50M 7.16M -11.71M -
Accounts payable 2.67M 0.35M 4.37M 6.14M 3.39M
Accumulated other comprehensive income -2.45M -1.89M -2.20M -3.79M -
Common stock total equity - - - 0.83M -
Non currrent assets other 5.28M 0.58M 0.17M 21.26M -
Non current assets total 13.24M 7.46M 16.06M 36.08M 13.96M
Capital lease obligations 6.10M 4.45M 2.78M 0.47M -
Breakdown 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Type yearly yearly yearly yearly yearly
Date 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Investments -0.62M -0.31M -0.42M - -0.41M
Change to liabilities -11.41M -2.52M 7.01M -4.04M -36.80M
Total cashflows from investing activities -0.62M -0.31M -0.42M -0.29M -0.31M
Net borrowings 520.00M 520.00M 520.00M -0.36M -0.28M
Total cash from financing activities 620.24M 77.92M 50.55M 33.11M 43.85M
Change to operating activities 19.05M 3.60M -6.61M 3.70M -3.42M
Net income -78.78M -88.60M -52.70M -25.56M 6.60M
Change in cash 576.82M 5.37M 2.58M 6.76M 8.86M
Begin period cash flow 71.79M 66.42M 63.84M 20.10M 26.37M
End period cash flow 648.61M 71.79M 66.42M 26.86M 35.23M
Total cash from operating activities -41.58M -72.59M -48.11M -26.66M -35.14M
Issuance of capital stock 100.00M 75.00M 50.00M - 45.44M
Depreciation 2.51M 2.46M 2.00M 1.47M 1.49M
Other cashflows from investing activities - - -0.42M 0.00M 0.00M
Dividends paid - - - - 0.00M
Change to inventory - 3.60M -6.61M - 0.00M
Change to account receivables 0.97M -1.14M 0.21M 4.66M -25.34M
Sale purchase of stock - - - - 0.00M
Other cashflows from financing activities 545.24M 112.92M 0.55M 33.11M -1.59M
Change to netincome 26.07M 13.63M 4.59M 4.49M 3.56M
Capital expenditures 0.62M 0.31M 0.42M 0.12M 0.16M
Change receivables - - - - 0.00M
Cash flows other operating - - - - 0.00M
Exchange rate changes - - - - 0.00M
Cash and cash equivalents changes - - - - 0.00M
Change in working capital 8.62M -0.07M 0.62M 4.37M -51.18M
Stock based compensation 11.95M 12.80M 1.77M - 6.22M
Other non cash items 14.12M 0.50M -0.39M -28.14M 1.73M
Free cash flow -42.21M -72.89M -48.53M -26.78M -35.31M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SMMT
Summit Therapeutics PLC		 -1.08
6.06%		 16.75 6.87 - 753.90 33.10 6425.28 -4.18
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Summit Therapeutics PLC

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

601 Brickell Key Drive, Miami, FL, United States, 33131

650 460 8308

https://www.summittxinc.com

105

Name Title Year Born
Mr. Robert W. Duggan CEO & Exec. Chairman 1944
Dr. Mahkam Zanganeh D.D.S., M.B.A., MBA Co-CEO, Pres & Director 1970
Dr. Urte Gayko Ph.D. Head of Regulatory Affairs, Quality Assurance & Safety and Director 1971
Prof. Dame Kay Davies DBE, FRS CBE Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor 1951
Mr. Ankur Dhingra Chief Financial Officer 1976
Ms. Michelle Avery Director of Investor Relations NA
Dr. Elaine Carla Stracker J.D., Ph.D. Head of Compliance? & Gen. Counsel 1961
Mr. Campbell Hair Head of HR? NA
Dr. Anne Heatherington Head of Clinical Devel. and Quantitative Sciences NA
Ms. Divya Chari Head of Global Clinical Operations 1968

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…